AnHeart Therapeutics Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Employees
-
140
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$397M
- Investors
-
1
AnHeart Therapeutics General Information
Description
Operator of a biopharmaceutical company intended to improve the lives of cancer patients. The company develops a pipeline of novel precision therapies for people with cancer, enabling medical professionals to improve human health and quality of life with required medical advancements.
Contact Information
Website
www.anhearttherapeutics.com(Operating Subsidiary)
Corporate Office
- 777 Third Avenue
- Suite 1704
- New York, NY 10017
- United States
Corporate Office
- 777 Third Avenue
- Suite 1704
- New York, NY 10017
- United States
AnHeart Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 09-Apr-2024 | $397M | Completed | Pre-Clinical Trials | ||
| 3. Early Stage VC (Series B) | 01-Sep-2021 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A1) | 10-Aug-2020 | $24M | $39M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 15-May-2019 | $15M | $15M | Completed | Pre-Clinical Trials |
AnHeart Therapeutics Comparisons
Industry
Financing
Details
AnHeart Therapeutics Competitors (3)
One of AnHeart Therapeutics’s 3 competitors is Arcus Biosciences, a Formerly VC-backed company based in Hayward, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arcus Biosciences | Formerly VC-backed | Hayward, CA | ||||
| Rain Oncology | Formerly VC-backed | Newark, CA | ||||
| Cellectar Biosciences | Formerly Accelerator/Incubator backed | Florham Park, NJ |
AnHeart Therapeutics Patents
AnHeart Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025045203-A1 | Heterocyclic compound, and intermediate and use thereof | Inactive | 01-Sep-2023 | ||
| JP-2025515952-A | Method for preparing 3,6-disubstituted imidazo[1,2-b]pyridazine compounds | Pending | 18-May-2022 | ||
| WO-2023220967-A1 | Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compounds | Inactive | 18-May-2022 | ||
| CA-3223035-A1 | Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof | Pending | 01-Jul-2021 | ||
| WO-2023272701-A1 | Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof | Inactive | 01-Jul-2021 | C07D487/04 |
AnHeart Therapeutics Signals
AnHeart Therapeutics Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cenova Capital | Venture Capital | Minority | ||
| China Merchants Venture Capital | Corporate Venture Capital | Minority | ||
| Decheng Capital | Venture Capital | Minority | ||
| Fuzhuo Investment | Venture Capital | Minority | ||
| Innovent Biologics | Corporation | Minority |
AnHeart Therapeutics FAQs
-
When was AnHeart Therapeutics founded?
AnHeart Therapeutics was founded in 2018.
-
Where is AnHeart Therapeutics headquartered?
AnHeart Therapeutics is headquartered in New York, NY.
-
What is the size of AnHeart Therapeutics?
AnHeart Therapeutics has 140 total employees.
-
What industry is AnHeart Therapeutics in?
AnHeart Therapeutics’s primary industry is Biotechnology.
-
Is AnHeart Therapeutics a private or public company?
AnHeart Therapeutics is a Private company.
-
What is the current valuation of AnHeart Therapeutics?
The current valuation of AnHeart Therapeutics is .
-
What is AnHeart Therapeutics’s current revenue?
The current revenue for AnHeart Therapeutics is .
-
How much funding has AnHeart Therapeutics raised over time?
AnHeart Therapeutics has raised $100M.
-
Who are AnHeart Therapeutics’s investors?
Cenova Capital, China Merchants Venture Capital, Decheng Capital, Fuzhuo Investment, and Innovent Biologics are 5 of 11 investors who have invested in AnHeart Therapeutics.
-
Who are AnHeart Therapeutics’s competitors?
Arcus Biosciences, Rain Oncology, and Cellectar Biosciences are competitors of AnHeart Therapeutics.
-
When was AnHeart Therapeutics acquired?
AnHeart Therapeutics was acquired on 09-Apr-2024.
-
Who acquired AnHeart Therapeutics?
AnHeart Therapeutics was acquired by Nuvation Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process